Molecular Mechanisms of Treatment Resistance in Glioblastoma

Area of Science:

• Neuro-oncology
• Cancer biology
• Molecular mechanisms of disease

Background:

• Glioblastoma is the most common and lethal primary adult brain tumor.
• Current standard-of-care treatments have seen little advancement in over 20 years, highlighting a significant unmet clinical need.
• Key challenges in glioblastoma treatment include overcoming the blood-brain barrier, addressing tumor heterogeneity, and navigating the immunosuppressive tumor microenvironment.

Purpose of the Study:

• To review the innate and adaptive molecular mechanisms of glioblastoma treatment resistance.
• To emphasize the intrinsic challenges in glioblastoma therapy: blood-brain barrier penetration, tumoral heterogeneity, and the tumor microenvironment.
• To explore resistance mechanisms against conventional treatments, targeted therapies, and immunotherapies.

Main Methods:

• Literature review of scientific publications.
• Analysis of molecular mechanisms underlying glioblastoma development and treatment resistance.
• Synthesis of information on therapeutic challenges and resistance pathways.

Main Results:

• Glioblastoma exhibits significant intra- and intertumoral heterogeneity.
• The blood-brain barrier poses a major obstacle for drug delivery.
• Redundant signaling pathways and an immunosuppressive microenvironment contribute to treatment failure.

Conclusions:

• Understanding the complex molecular mechanisms of glioblastoma resistance is crucial for therapeutic advancement.
• Addressing the blood-brain barrier, tumor heterogeneity, and microenvironment are critical for improving patient outcomes.
• Novel therapeutic strategies are needed to overcome resistance to existing and emerging glioblastoma treatments.